Recent guidance from the U.S. Food and Drug Administration provides much-needed guidance on the usage of artificial intelligence in producing information to support regulatory decision-making regarding drug safety, with implications ranging from life cycle maintenance to AI tool acquisition, say attorneys at Covington.
